Thursday, February 13, 2014
A Massachusetts team has designed an in vivo shRNA
screen to discover immunosuppressive tumor targets that can be blocked to
improve the efficacy of T cell immunotherapies.1 The screening
system shows that current checkpoint inhibitors are barely scratching the
surface of potential targets to modulate and may enable new directions in
Corresponding author Kai Wucherpfennig said that the in vivo assay is a
first attempt to find previously unknown genes that could be regulated to help
T cells circumvent the immunosuppressive tumor microenvironment.
T. SciBX 7(6); doi:10.1038/scibx.2014.162 Published online Feb. 13, 2014
1. Zhou, P. et
al. Nature; published online Jan. 29, 2014; doi:10.1038/nature12988
Contact: Kai W. Wucherpfennig, Dana-Farber Cancer Institute, Boston, Mass. e-mail: email@example.com
AND INSTITUTIONS MENTIONED
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
Genomics Institute of the Novartis Research Foundation, San Diego, Calif.
Harvard Medical School, Boston, Mass.
The Johns Hopkins University School of Medicine, Baltimore, Md.
Jounce Therapeutics Inc., Cambridge, Mass.
Institute of Technology,
for BioMedical Research,
Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan